Contineum director granted 19,000 stock options
Contineum Therapeutics, Inc. director Lori Lyons-Williams received a grant of stock options covering 19,000 shares of Class A Common Stock under the company’s 2024 Equity Incentive Plan.
Rhea-AI Filing Summary
Contineum Therapeutics, Inc. director Lori Lyons-Williams received a grant of stock options covering 19,000 shares of Class A Common Stock under the company’s 2024 Equity Incentive Plan. The options have an exercise price of $14.19 per share and expire on June 25, 2036.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic annual option award to each continuing non-employee director after the regular annual stockholder meeting. The option vests in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, subject to her continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 19,000 shares
Grant/Award
1 txn
Insider
Lyons-Williams Lori
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 19,000 contracts (Direct)
Footnotes (1)
- F1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Key Figures
Option grant size: 19,000 shares
Exercise price: $14.19 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Option grant size
19,000 shares
Stock options for Class A Common Stock granted to director
Exercise price
$14.19 per share
Strike price of granted stock options
Expiration date
June 25, 2036
Option term end date for the grant
Shares underlying options
19,000 shares
Class A Common Stock underlying the derivative security
Vesting trigger date
June 26, 2027
Earlier of this date or next regular annual stockholder meeting
Key Terms
2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, Class A Common Stock
4 terms
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Contineum Therapeutics (CTNM) report for Lori Lyons-Williams?
Contineum Therapeutics reported that director Lori Lyons-Williams received a grant of stock options for 19,000 shares of Class A Common Stock. These options were issued as part of the company’s 2024 Equity Incentive Plan and its Non-Employee Director Compensation Program.
What are the key terms of the 19,000 Contineum (CTNM) stock options granted?
The granted options cover 19,000 shares of Class A Common Stock with an exercise price of $14.19 per share. They expire on June 25, 2036 and were awarded at $0.00 grant price as compensation, not an open-market purchase.
When do Lori Lyons-Williams’ Contineum (CTNM) stock options vest?
The options vest in full on the earlier of June 26, 2027, the one-year anniversary of the grant date, or the next regular annual meeting of stockholders. Vesting is conditioned on her continuous service as a non-employee director through that date.
Under what plan were the 19,000 Contineum (CTNM) options granted?
The 19,000 options were granted under Contineum’s 2024 Equity Incentive Plan and its Non-Employee Director Compensation Program. That program provides an automatic option grant to each continuing non-employee director after each regular annual stockholder meeting, aligning director compensation with equity.
Is the Contineum (CTNM) Form 4 transaction a market purchase or compensation grant?
The Form 4 reflects a compensation grant, not an open‑market purchase or sale. Lori Lyons-Williams received stock options at $0.00 grant price with a $14.19 exercise price, issued automatically under the non‑employee director compensation program following the annual stockholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
